Using Tolerance Intervals for Setting Process Validation Acceptance Criteria Richard K. Burdick —Amgen, Inc. (CO) Graybill Conference June, 2008.

Slides:



Advertisements
Similar presentations
Chapter 2 The Process of Experimentation
Advertisements

Medical Device Software Development
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Breakout Session 4: Personalized Medicine and Subgroup Selection Christopher Jennison, University of Bath Robert A. Beckman, Daiichi Sankyo Pharmaceutical.
Chapter 9A Process Capability and Statistical Quality Control
1 Manufacturing Process A sequence of activities that is intended to achieve a result (Juran). Quality of Manufacturing Process depends on Entry Criteria.
Reprocessing Biotech Products
1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,
Measurement Systems Analysis with R&R INNOVATOR Lite TM The House of Quality presents.
Batch Reworking and Reprocessing
Mitigating Risk of Out-of-Specification Results During Stability Testing of Biopharmaceutical Products Jeff Gardner Principal Consultant 36 th Annual Midwest.
15 de Abril de A Meta-Analysis is a review in which bias has been reduced by the systematic identification, appraisal, synthesis and statistical.
Copyright (c) 2009 John Wiley & Sons, Inc.
Chapter 10 Quality Control McGraw-Hill/Irwin
Software Quality Control Methods. Introduction Quality control methods have received a world wide surge of interest within the past couple of decades.
Simulation.
Six Sigma Quality Engineering
Lecture 10 Comparison and Evaluation of Alternative System Designs.
Stefan Franzén Introduction to clinical trials.
Pharmaceutical Product Quality Assurance Through CMC Drug Development Process Presented by Darlene Rosario (Aradigm) 21 October 2003 Meeting of the Advisory.
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.
COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.
Pilot Risk-Ranking Model to Prioritize Manufacturing Sites for GMP Inspections Advisory Committee for Pharmaceutical Science Manufacturing Subcommittee.
External Defibrillators: Recalls, Inspections, and the Quality System Regulation Melissa Torres Office of Compliance December 15, 2010.
VALIDATION OF RAW MATERIALS
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
Validation Tutorial This tutorial is designed to enhance knowledge of biotechnological/pharmaceutical processes. The topics covered within this tutorial.
Huzairy Hassan School of Bioprocess Engineering UniMAP.
Learnings from Pre-approval Joint Inspection of a GSK QbD Product with US-FDA & EMA and the application of Continuous Verification 17 May 2011, Beijing,
Application of the principles of QbD in vaccines production Andrea Pranti.
Principles of Assessment
Annex I: Methods & Tools prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY.
Quality Control McGraw-Hill/Irwin Copyright © 2012 by The McGraw-Hill Companies, Inc. All rights reserved.
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Inference in practice BPS chapter 16 © 2006 W.H. Freeman and Company.
Slide 1 May 2008 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008 QUALITY BY DESIGN.
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
Stefan Franzén Introduction to clinical trials.
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.
Quality by Design (QbD) Myth : An expensive development tool ! Fact : A tool that makes product development and commercial scale manufacturing simple !
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
A Qualitative Decision Making Tool to Aid in Defining the Number of Lots for a Process Validation Campaign Leslie Sidor — Amgen Inc Midwest Biopharmaceutical.
Brian Macpherson Ph.D, Professor of Statistics, University of Manitoba Tom Bingham Statistician, The Boeing Company.
Chapter 6. Control Charts for Variables. Subgroup Data with Unknown  and 
Design Space: Case Study for a Downstream Process Post Approval
Molecule-to-Market-Place Quality
The New Drug Development Process (www. fda. gov/cder/handbook/develop
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
IMPORTANCE OF STATISTICS MR.CHITHRAVEL.V ASST.PROFESSOR ACN.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
Chapter 7 Measuring of data Reliability of measuring instruments The reliability* of instrument is the consistency with which it measures the target attribute.
1/20/2016ENGM 720: Statistical Process Control1 ENGM Lecture 05 Variation Comparisons, Process Capability.
The Role of Experimentation in Individual and Team Innovation and Discovery Dan Frey Department of Mechanical Engineering Engineering Systems Division.
Department of Defense Voluntary Protection Programs Center of Excellence Development, Validation, Implementation and Enhancement for a Voluntary Protection.
What is a software? Computer Software, or just Software, is the collection of computer programs and related data that provide the instructions telling.
Chapter 51Introduction to Statistical Quality Control, 7th Edition by Douglas C. Montgomery. Copyright (c) 2012 John Wiley & Sons, Inc.
In the name of God. Common Technical Document On Biotech.
Medical Device Software Development
A custom designed sequential workflow
Process Capability and Capability Index
WHO Technical Report Series, No. 953, 2009
Quality System.
QUALITY BY DESIGN Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008.
Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.
Biological Science Applications in Agriculture
Introduction to Research Methods in Psychology
Presentation transcript:

Using Tolerance Intervals for Setting Process Validation Acceptance Criteria Richard K. Burdick —Amgen, Inc. (CO) Graybill Conference June, 2008

Using Tolerance Intervals for Setting Process Validation Acceptance Criteria “A worn-out academician’s adventure in the ‘real word’"

3 Operational Excellence Outline  Life at Amgen  Nonclinical statistics  Definitions for Process Characterization and Validation  Statistical Methods for Setting Process Validation Acceptance Criteria  Future Opportunities

4 Operational Excellence Amgen: A Biotechnology Pioneer  Founded in 1980, Amgen was one of the first biotechnology companies to successfully discover, develop and make protein-based medicines  Today, we’re leading the industry in its next wave of innovation by: –Developing therapies in multiple modalities –Driving cutting-edge research and development –Continuing to advance the science of biotechnological manufacturing

5 Operational Excellence Research and Development at Amgen Guiding Principles  Focus on serious illness  Be modality independent  Assess efficacy in patients  Seamless integration from research through commercialization Therapeutic Areas  Inflammation  Oncology  Hematology  Metabolic and bone disease  Neuroscience

6 Operational Excellence Nonclinical Statistics  Chemistry, Manufacturing, Controls (CMC) development establishes the process of manufacturing drug product to meet clinical requirements.  Work in both research and development and manufacturing.

7 Operational Excellence Nonclinical statisticians involved in…  R&D with –Assay validation –Process validation –Method transfer –Stability studies (storage conditions, shelf-life, expiry extensions) –DOE for process characterization –Establishment of specifications and process validation acceptance limits.  Manufacturing with –Maximization of yields –Control charting –Support in non-conformance reports (identification of assignable causes) –Raw materials inspection

8 Operational Excellence Timeframe of Characterization and Validation Activities Relative to Clinical Trials End of Phase II Clinical Trial CharacterizationValidation End of Phase III Clinical Trial and Commit to File Update CV documents

9 Operational Excellence Very Simple Process Diagram (Upstream) (Downstream) Diafiltered Medium (DFM) Filtered Purified Bulk (FPB)

10 Operational Excellence Process Characterization  Process Characterization is a precursor to process validation and is comprised of a set of documented studies in which operating parameters (inputs) are purposely varied to determine the effect on product quality attributes (outputs) and process performance.  Employs Failure Modes and Effects Analysis (FMEA) and Experimental Design

11 Operational Excellence Process Validation  Process validation provides the documented evidence that the process, when operated within established limits, can perform effectively and reproducibly to produce an intermediate, active pharmaceutical ingredient (API) or drug product meeting predetermined criteria and quality attributes.  Final drug product and API have specifications that must be met based on standards mandated by safety concerns and other factors.  However, intermediate process steps (which do not have mandated standards) have a number of acceptance criteria that must be met to demonstrate process consistency and the ability to meet final specifications.

12 Operational Excellence Process Validation Acceptance Criteria  Process Validation Acceptance Criteria (PVAC) A set of numerical limits that when exceeded, signals a significant departure from operating conditions or product quality.  Set prior to initiation of the validation campaign.  Establishing PVAC is one of the greatest challenges in the development of a commercial biopharmaceutical manufacturing process.

13 Operational Excellence Definitions  Operating Parameter (OP): Parameter that can be directly manipulated (input)  Performance Parameter (PP): In-process parameter or measurement used for process performance evaluation (output)  Normal Operating Range (NOR): A range for an operating parameter that is listed in the Manufacturing Procedure. Frequently based on equipment and/or process capability.

14 Operational Excellence Setting PVAC-A personal history  My involvement with the ACO process development (PD) group began as a discussion concerning analysis of one-off studies conducted at 3 times outside the NOR.  Questions concerned how to determine the operating parameters (OPs) that were most important in the process.  I helped them analyze the data in a manner they were comfortable with, and gained their confidence so that I could work with them on future projects.

15 Operational Excellence Setting PVAC-A personal history  My involvement with the ACO process development (PD) group began as a discussion concerning analysis of one-off studies conducted at 3 times outside the normal operating range (NOR).  Questions concerned how to determine the operating parameters (OPs) that were most important in the process.  I helped them analyze the data in a manner they were comfortable with, and gained their confidence so that I could work with them on future projects. Lesson 1: Sometimes it is best to answer the client’s question instead of telling them what they are doing wrong.

16 Operational Excellence  When the discussion of setting PVAC came up, I researched the history of setting PVAC at ACO: –There was some sentiment for “3 sigma” rules –JMP Prediction Profiler at the extremes of the NOR had been used with previous projects (these limits are actually the confidence intervals on the average for a given value of the OP). –Data sets from robustness and edge of range studies were not being combined. In some cases, only centerpoints were being used to determine PVAC.

17 Operational Excellence  When the discussion of setting PVAC came up, I researched the history of setting PVAC at ACO: –There was some sentiment for “3 sigma” rules –JMP Prediction Profiler at the extremes of the NOR had been used with previous projects (these limits are actually the confidence intervals on the average for a given value of the OP). –Data sets from robustness and edge of range studies were not being combined. In some cases, only centerpoints were being used to determine PVAC. Lesson 2: Find out why certain methods were used in the past. Can you use these approaches as a starting point, and demonstrate continuous improvement?

18 Operational Excellence Construction of PVAC  I suggested we use tolerance intervals for defining PVAC because they describe the long range expected behavior of the process.  Bench data derived from process characterization experimental design studies can be combined with large-scale runs to compute tolerance intervals at set- point conditions (or any other point in the NOR) centered at either commercial or clinical scale.

19 Operational Excellence TI Depends on OP

20 Operational Excellence Type of TIs  If all OPs are fixed effects, then exact one-sided tolerance intervals can be constructed based on the non-central t distribution –See, e.g., Graybill (1976, pages )  Exact two-sided tolerance intervals are available (Eberhardt, Mee, and Reeve, 1989), but computationally complex. –Various two-sided approximations have been suggested Weissberg, A. and G. H. Beatty (Technometrics,1960) Lee, Y. and T. Mathew (JSPI, 2004) Liao, C. T., Lin, T. Y., and Iyer, H. (Technometrics, 2005).

21 Operational Excellence One other refinement  Many times, the PC models involve random effects such as the raw materials that feed into a process step.  In this case, the fixed effect methods can not be applied for computing tolerance intervals.  Generalized Inference provides an approach for computing tolerance intervals with a random effect. Liao, C. T., Lin, T. Y., and Iyer, H. (Technometrics, 2005) Based on generalized fiducial intervals

22 Operational Excellence One other refinement  Many times, the PC models involve random effects such as the raw materials that feed into a process step.  In this case, the fixed effect methods can not be applied for computing tolerance intervals.  Generalized Inference provides an approach for computing tolerance intervals with a random effect. Liao, C. T., Lin, T. Y., and Iyer, H. (Technometrics, 2005) Based on generalized fiducial intervals Lesson 3: Continue to make improvements and demonstrate you are willing to continually improve your work.

23 Operational Excellence Example—Purification Column  Purification is used in a biopharmaceutical product to separate desired protein from unwanted materials.  This example considers one such column where the response is modeled as a function of a fixed OP (coded -1 to +1) and the random effect feed material.  Response is a purity measure in %.

24 Operational Excellence

25 Operational Excellence

26 Operational Excellence  Using the GCI approach, the computed tolerance interval for the OP=0 (setpoint condition) is from %

27 Operational Excellence Plot of Tolerance Intervals and Runs with OP = 0

28 Operational Excellence Future Opportunities  FDA initiative for Quality by Design.  ICH Q8 Appendix on movement within the proven acceptable range (PAR)—also referred to as “Design Space”.

29 Operational Excellence Design Space (ICH Q8) Unexplored Space Knowledge Space “Design”Space NOR Unexplored Space Knowledge Space “ Design ” Space NOR PAR (Proven Acceptable Range) Explored with Acceptable Performance NOR (Normal Operating Range) Operating Strategy based on Business/EquipmentRequirements Explored Space DOE Modeling Prior Knowledge First Principles Risk Assessment to Prioritize Investigation Control Strategy Specifications Tolerances

30 Operational Excellence